Abstract: A liquid pharmaceutical agent formulation suitable for oral or nasal delivery comprises a proteinic pharmaceutical agent, water and at least two absorption enhancing compounds. The absorption enhancing compounds are selected from sodium salicylate, sodium lauryl sulphate, disodium ethylenediaminetetraacetic acid (disodium EDTA), oleic acid, linoleic acid, monoolein, lecithin, lysolecithin, deoxycholate, sodium deoxycholate, chenodeoxycholate, taurodeoxycholate, glycochenodeoxycholate, polyoxyethylene X-lauryl ether wherein X is from 9 to 20, sodium tauro-24, 25-dihydrofusidate, polyoxyethylene ether, polyoxyethylene sorbitan esters, p-t-octylphenoxypolyoxyethylene, N-lauryl-.beta.-D-maltopyranoside, 1-dodecylazacycloheptane-2-azone and phospholipids, wherein the amount of each of the absorption enhancing compounds is present in a concentration of from 1 to 10 wt./wt. % of the total formulation. Preferably each of the absorption enhancing compounds is present in a concentration of from 1.5 to 3.5 wt./wt.

Abstract: A process is provided for the production of piroxicam tablets. According to the process, a solution of a water-soluble high-molecular substance is added to a mixture of piroxicam and lactose. The resultant mixture is granulated and then compressed into tablets.

Abstract: A process for preparing biodegradable microparticles comprising a biodegradable polymeric binder and a biologically active agent. A first phase, comprising the active agent and the polymer, and a second phase are pumped through a static mixer into a quench liquid to form microparticles containing the active agent. Preferably, a blend of at least two substantially non-toxic solvents, free of halogenated hydrocarbons, is used to dissolve or disperse the agent and dissolve the polymer.

Abstract: A combination bulk-forming and osmotic laxative is provided by combining a bulk-forming laxative in the form of psyllium hydrophilic mucilloid with an osmotic laxative such as lactitol. The addition of the osmotic laxative to the bulk-forming laxative with a binder solution and subsequent drying produces an improved laxative in granulate form which is directly compressible into tablets.

Abstract: Disclosed herein is a process for preparing biodegradable microparticles comprising a biodegradable polymeric binder and a biologically active agent, wherein a blend of at least two substantially non-toxic solvents, free of halogenated hydrocarbons, is used to dissolve or disperse the agent and dissolve the polymer. The solvent blend containing the agent and polymer is dispersed in an aqueous solution to form microdroplets. The resulting emulsion is then added to an extraction medium preferably containing at least one of the solvents of the blend, whereby the rate of extraction of each solvent is controlled, whereupon the biodegradable microparticles containing the biologically active agent are formed.

Abstract: The foregoing invention relates to a new microbubble preparation and thrombolytic therapy which relies on microbubbles and ultrasound for its lytic activity. The pharmaceutical composition of the invention comprises a liquid solution of microbubbles with an internal atmosphere enhanced with the perfluorocarbon gas which cavitate in the presence of an ultrasound field following intravenous injection or infusion of said composition into said host. For thrombolysis the area of a thrombus is exposed to an ultrasound field in the presence of the microbubbles and significant lysis is experienced. The method and pharmaceutical composition of the invention exhibit thrombolytic properties similar to those of other thrombolytic agents such as urokinase and are less toxic and are clot specific in that they do not introduce a systemic lytic state to a said animal.

Abstract: This invention pertains to the use of a combination of angiotensin inhibitors and nitric oxide stimulators to slow and reverse the process of fibrosis in the body. This combination of medicaments is particularly useful in the treatment of a variety of cardiovascular fibrotic pathologies, such as that associated with left ventricular hypertrophy secondary to hypertension, myocardial infarction, and myocarditis.

Abstract: This invention is directed to a multilayered controlled release pharmaceutical dosage form. More particularly the dosage form is adapted for water soluble drugs and comprises a plurality of coated particles wherein each has multiple layers about a core containing a drug active whereby the drug containing core and at least one other layer of drug active is overcoated with a controlled release barrier layer and preferably an outer layer of additional drug is adapted for immediate release to preferably provide one immediate releasing layer and at least two controlled releasing layers of a water soluble drug from the multilayered coated particle.

Abstract: A deodorizer comprises a hydrophilic solvent extract of fruit-bodies of champignon mushroom or powder of the extract as an effective component. The extract of champignon mushroom used as an effective component can be prepared by a method which comprises the step of immersing the mushroom in a hydrophilic solvent at a temperature ranging from 60.degree. to 100.degree. C. for 15 minutes to 2 hours to perform extraction. The extract can further be treated to obtain the effective components in the form of powder.

Abstract: A granulation process for preparing a solid dosage form containing acetaminophen and diphenhydramine hydrochloride, as active agents is disclosed. In addition, the solid dosage form produced by the process is described.

Abstract: Described herein is a drug delivery system useful to deliver drugs at low dosage levels to patients in a sustained fashion and at a controlled rate. The system comprises a wettable polymeric matrix in which is dispersed a multiplicity of particles containing a substantially homogeneous blend of osmotically active excipient and not more than about 10% by weight of drug. The system is particularly well suited for delivery of therapeutic macromolecules such as protein drugs. Delivery of epidermal growth factor is exemplified.

Abstract: At least one serine compound corresponding to the Formula I: ##STR1## in which R and R', which are identical or different, represent a linear or branched hydrocarbon radical having from 8 to 30 carbon atoms, or the D-optical isomer of Formula I, the L-optical isomer of Formula I, or a non-racemic mixture of at least two of the optical isomers; the preparation of these compounds and their use, especially in cosmetic or pharmaceutical compositions intended for treating or caring for the hair or for the skin.

Abstract: A personal care composition is provided, composing (A) an effective amount of a polyalkylsiloxane copolymer having a melting point of from about -40.degree. C. to about +40.degree. C., and being selected from various specific polyalkylsiloxane copolymer fluids or polyalkylsiloxane copolymer resins; and (B) a cosmetically acceptable carrier medium, wherein the polyalkylsiloxane copolymer contains mixtures of linear lower alkyl side chains and linear higher alkyl side chains or mixtures of linear alkyl side chains and branched alkyl side chains. The polyalkylsiloxane copolymers used in the composition are fluids or soft waxes at body temperature and have improved application and payout and better substantivity and hair conditioning properties.

Abstract: A bath composition is disclosed, which comprises a xanthine derivative or a .beta.-adrenergic stimulants. The bath composition, as dissolved in bath water, gives a moist (fresh) feel to the skin and a warm feel to the body. A method for imparting a moist feel to the skin and improving a warm feel of the body is also disclosed.

Abstract: The invention provides a solid preparation having a quick and pH-independent dissolution with an excellent bioavailability for a drug that is otherwise sharply depressed in solubility with pH elevation. This solid preparation contains granules each comprising a fine particulate core coated with a solid solution comprising a drug which is pH-dependent in solubility and may be released from an enteric base-containing composition at low pH and an enteric base.

Abstract: A solid cosmetic composition comprising a freeze-dried product of an aqueous solution containing at least a water-soluble substance which is solid at normal temperature, and a water-soluble polymer as a thickener or a humectant, which solid cosmetic composition is used after being dissolved in a solvent.

Abstract: An inorganic coating film having improved water repellency is provided. The improved surface is provided by treating an inorganic coating film with a material that is reached or adsorbed on the surface of the inorganic coat to increase water repellency. The inorganic coating to be treated may be a silicon dioxide film. The materials used to treat the film include: (1) halogenated silane compounds; (2) silane compounds having a structure including at least one bond selected from Si--H, Si--OH, Si--OR, Si--SH and Si--SR, wherein R is an organic group; (3) silane compounds having a structure including at least one of ##STR1## wherein R1, R2 and R3 are hydrogen or an organic group and (4) reactive organic compounds having a fluorine substituting group, hydrogen fluoride or a metal fluoride.

Abstract: An improved preserving fluid and method has been developed. The fluid is a mixture including glutaraldehyde, an aromatic ether of ethanol e.g. phenoxyethanol, at least one alcohol, and a polyhydric alcohol humectant. The formulation has no formaldehyde.

Abstract: The present invention is a method of preparing rapidly dissolving comestible units such as tablets. The present invention also includes an apparatus for making the comestible units and the units themselves. The product prepared in accordance with the present invention can include active ingredients and is capable of dissolving in the mouth of the consumer within several seconds. The unit dosage forms prepared in accordance with the present invention are particularly useful as antacids and as a delivery vehicle for biologically active ingredients, especially those which are ideally combined with antacid ingredients in order to ameliorate the effects of antacid environment.

Abstract: A method for treating poultry litter which inhibits ammonia volatilization and reduces soluble phophorus levels in the litter. The method comprises the addition of alum to litter in an amount sufficient to maintain the litter pH at values low enough to inhibit ammonia volatilization. The addition of alum, iron or calcium compounds to litter also effectively precipitates soluble phosphorus in litter, thereby reducing the amount of soluble phosphorus runoff from fields receiving litter.